Normal Response of Active GLP-1 like Substances Level to Test Meal in Non-Obese Type 2 Diabetic Japanese Patients with Complications and Receiving Treatments

Kuyzi Kamoi1, Nobumasa Ohara2,3, Ikarashi Tomoo2,3, You Shinozaki1,2, Kazuo Furukawa1,2 and Hideo Sasaki3

1Center of Diabetes and Endocrine & Metabolism Disease, Nagaoka Red Cross Hospital, Nagaoka, Niigata 940-2085, Japan
2Department of Endocrinology and Metabolism, Niigata University, Niigata, Niigata 951-8510, Japan
3Diabetes Center, Niigata Medical Center, Niigata, Niigata 950-2022, Japan
4Department of Health and Nutrition, University of Niigata Prefecture, Niigata, Niigata 950-8680, Japan

Abstract

Background: Study has shown no significant differences in basal and postprandial plasma active glucagon-like peptide-1 (p-active GLP-1) levels following test meal (TM) between complication- and treatment-naive non-obese Japanese patients with type 2 diabetes (T2DM) and controls.

Methods: In non-obese Japanese patients with T2DM (n=23, group 1) and healthy individuals as control (n=13, group 2), blood levels of plasma glucose (PG), serum insulin (s-IRI), serum C-peptide (s-CPR) and p-active GLP-1 like substances (p-active GLP-1-S) were measured 0, 30, and 60 min after TM (520-560 kcal, 23% fat, 60% carbohydrate and 17% protein). HbA1c levels were also measured in the groups. Patients with mean of 9.2 years disease had various complications and treatment with diet, exercise and/or oral medical drugs except incretin-related drugs for hyperglycemia.

Results: There was no significant difference in mean of sex, age, or BMI between groups. Means of HbA1c and basal and postprandial PG with area under curve (AUC), and HOMA-R were significantly higher in group 1 than in group 2. Means of HOMA-B and insulinogenic index after ingestion of TM were significantly lower in group 1 than in group 2. However, there were no significant differences in means of basal and postprandial with AUC levels of s-IRI, s-CPR and p-active GLP-1-S levels between groups.

Conclusion: These results indicated that a response of p-active GLP-1-S to TM in non-obese Japanese patients with T2DM associated with a long duration of disease, various complications and various treatments with except incretin-related drugs was similar to those in non-obese healthy individuals.

Keywords: Active GLP-1; Test meal; BMI; Non-obesity; Type 2 DM

Background

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinoctropic polypeptide (GIP) are secreted in response to ingestion of nutrients. In the circulation, GLP-1 and GIP are rapidly inactivated by dipeptidyl peptidase-IV (DPP-IV), which cleaves off two N-terminal amino acids [1].

Vilsbøll et al. reported that a low response in plasma active GLP-1 (p-active GLP-1) to ingestion of breakfast test meal (TM) was seen in European patients with type 2 diabetes mellitus (T2DM) [2], while Lee et al. reported that there was no significant difference in a response of p-active GLP-1 levels following TM in complication- and treatment-naive Japanese patients with T2DM [3]. Our preliminary study supported the findings of Lee et al. by the facts that postprandial p-active GLP-1 like substances levels following TM were not decreased while Lee et al. reported that there was no significant difference in a response of p-active GLP-1 levels following TM in complication- and treatment-naive Japanese patients with T2DM (unpublished data).

To clarify a response of active GLP-1 levels in duration of disease-, complication- and treatment-non-obese Japanese patients with T2DM, we reexamined the effects of a TM similar to the one used by Vilsbøll et al. [2] on basal and postprandial levels of p-active GLP-1 like substances (p-active GLP-1-S) after TM in non-obese Japanese patients with T2DM, who had a long duration of disease and various kinds of complications, and received various kinds of drugs except incretin-related for diseases.

Methods

Subjects

Non-obese (BMI <25.0 kg/m2) Japanese patients with T2DM (n=23, group 1) and non-obese Japanese healthy subjects with normal glucose tolerance (NGT) as control (n=13, group 2) (Table 1) were studied, in which the definition of non-obesity was based on the criteria of Japan Society for the Study of Obesity [4]. Patients with obesity and insulin treatment were excluded from this study, because that such factor may influence the p-active GLP-1 levels [5]. Groups 1 and 2 were matched by sex, age, and BMI. Demographic characteristics of the participants are presented in Table 1. Diabetic patients were diagnosed by the World Health Organization criteria [6] with ≥6.5% of HbA1c.
All patients had T2DM with around 9 years of disease from discovery (Table 1). Therefore, some had retinopathy, nephropathy or peripheral neuropathy, and asymptomatic coronary heart disease or asymptomatic cerebral vascular diseases. The occurrences of retinopathy and nephropathy were examined by ophthalmologist and by mean of albuminuria. To diagnose diabetic peripheral neuropathy, the patient's history of symptoms for the foot and ankle was obtained and performed simple in-office tests on the feet and legs. This evaluation included assessment of the patient's reflexes, light touch and vibration. In some cases, additional neurologic tests were performed, respectively. The macrovascular complications were defined by past medical history. They were treated with diet, exercise and/or oral medical drugs for hyperglycemia. Oral medical drugs were consisted of α-glucosidase inhibitors (α-GI), sulfonylurea (SU), biguanide (BG), thiazolidine (TZD) or combinations with them (Table 1). Some patients were treated with anti-hyperlipidemic or anti-hypertensive drugs.

Non-obese control subjects were recruited from persons with NGT for a 75gOGTT with < 6.5% of HbA1c (NGSP). None of the participants had a history of gastrointestinal disease, anemia, or impaired liver function and none were receiving any other medications.

Written informed consent was obtained from all subjects after informing them of purpose and nature of the study. This study was performed in accordance with the Declaration of Helsinki and with the approval of our hospital ethics committees.

Study design
The study design was previously reported [5]. After 10-hours overnight fast, subjects were studied at 9:00 a.m. The TM (520-560 kcal) comprised of 23% fat, 60% carbohydrate and 17% protein [5]. Patients stopped all medications during the study.

Insulin resistance and beta-cell function were assessed using HOMA-R and HOMA-β (%), which were calculated by the equations reported previously [3,5,7]. Insulinogenic index was also calculated [3,5].

Blood samples were collected in ice-cooled tubes from the inserted cannula immediately before, and 30 and 60 minutes after ingestion of the TM and were separated by centrifugation at 4°C for later determination of PG, s-IRI, serum immunoreactive C-peptide (s-CPR) and p-active GLP-1-S levels. The sample collected was also used to measure HbA1c levels. They for active GLP-1-S and glucose were collected in ice-cooled vacutainers containing EDTA with 10μl DPP-IV inhibitor (diprotin) per mL of blood and in vacutainers containing NaF, respectively [5].

Increment levels of PG, s-IRI, s-CPR and p-active GLP-1-S after ingestion of the TM as AUC were calculated as method reported previously [5].

Assay methods
All assay methods were same as previous reports [5]. Briefly, HbA1c was measured using high-performance liquid chromatography. The value was expressed as NGSP equivalence. PG was measured by using oxidase method. S-IRI and s-CPR were measured by two-site sandwich immunoassay kits [5]. The intra- and inter-assy coefficients of variation are both <5%.

P-active GLP-1 was measured in the unextracted sample by two-site sandwich enzyme immunoassay using a commercially available ELISA active GLP-1 kit (Linco Research, St. Charles, MO, USA) at SRL, Inc. (Tokyo, Japan) as previously reported method [5]. As foreign substances in unextracted samples might interfere in the assay [7,8], we represented that the value measured by this kit as p-active GLP-1-S. The antibody provided with kit specifically recognizes the N-terminal region of active GLP-1 (7-36 and 7-37), but not other forms of GLP-1 (1-36, 1-37, 9-36 and 9-37). The limit of detection for this assay is < 2.0 pmol/L. The intra- and inter-assay coefficients of variation were both <13% [5].

Statistical methods
Results are expressed as means ± SEM. Differences between means of basal variables, insulinogenic index or AUC in groups were evaluated statistically by chi square or unpaired t tests with or without Welch’s correction [3,5].

The same method reported previously [5] was used to determine how the response was affected by TM in groups. Two-tailed p-values < 0.05 were considered as statistically significant. Analysis was performed using GraphPad Prism version 5.04 (GraphPad Software, La Jolla, CA, USA).

Results
Basal levels
There was no significant difference in mean of sex, age or BMI between groups. Means of HbA1c and PG, and HOMA-R were significantly higher in group 1 than in group 2, whereas mean of

<table>
<thead>
<tr>
<th>Type 2 diabetic patients</th>
<th>Control</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>23</td>
<td>13</td>
</tr>
<tr>
<td>Age</td>
<td>58 ± 2.7</td>
<td>52 ± 2</td>
</tr>
<tr>
<td>Gender (males/females)</td>
<td>18/5</td>
<td>5/8</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>21 ± 0.3</td>
<td>21 ± 0.5</td>
</tr>
<tr>
<td>HbA1c (%) (NGSP)</td>
<td>9.1 ± 0.3</td>
<td>5.4 ± 0.01</td>
</tr>
<tr>
<td>Plasma glucose (mg/dL)</td>
<td>151 ± 9</td>
<td>92 ± 2</td>
</tr>
<tr>
<td>Serum immunoreactive insulin (μU/mL)</td>
<td>5.2 ± 0.6</td>
<td>3.7 ± 0.6</td>
</tr>
<tr>
<td>HOMA-R</td>
<td>1.9 ± 0.2</td>
<td>0.8 ± 0.1</td>
</tr>
<tr>
<td>HOMA-β (%)</td>
<td>25.1 ± 3.4</td>
<td>80.1 ± 5.1</td>
</tr>
<tr>
<td>Serum immunoreactive C-peptide (ng/mL)</td>
<td>1.7 ± 0.1</td>
<td>1.4 ± 0.1</td>
</tr>
<tr>
<td>Plasma immunoreactive active GLP-1 like substance (pmol/L)</td>
<td>4.0 ± 0.5</td>
<td>2.6 ± 0.5</td>
</tr>
<tr>
<td>Duration of diabetes from discovery (year)</td>
<td>9.2 ± 1.5</td>
<td>9.2 ± 1.5</td>
</tr>
<tr>
<td>Retinopathy (NDR/SDR/PPDR/PDR)</td>
<td>19/1/0/3</td>
<td></td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Nephropathy (Normo/Micro/Macro)</td>
<td>17/5/1</td>
<td></td>
</tr>
<tr>
<td>Macroangiopathy (asymptomatic)</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Diabetic treatment (α-GI/BG/TZD/SU)</td>
<td>1/15/12/12</td>
<td></td>
</tr>
<tr>
<td>Dyslipidemia treatment</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Hypertension treatment</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Clinical characteristics of complications- and treatment-non-naïve non-obese Japanese patients with type 2 diabetes mellitus and non-obese Japanese controls with normal glucose tolerance.

Data are expressed as means ±SEM. Each value was collected in the morning with fasting. HOMA-R = fasting immunoreactive insulin (IRI) level × fasting plasma glucose (PG) level /405. HOMA-β =fasting IRI level × fasting plasma glucose (PG) level /360 (fasting PG level - 63). Differences between the means in two groups were statistically evaluated by chi square or unpaired t tests with or without Welch’s correction. Two-tailed values of p<0.05 were defined as statistically significant.


Citation: Kamoi K, Ohara N, Tomoo I, Shinozaki Y, Furukawa K (2011) Normal Response of Active GLP-1 like Substances Level to Test Meal in Non-Obese Type 2 Diabetic Japanese Patients with Complications and Receiving Treatments. J Diabetes Metab 2:147. doi:10.4172/2155-6156.1000147
HOAMA-β was significantly lower in group 1 than in group 2. However, there was no significant difference in mean of s-IRI, s-CPR or p-active GLP-1-S levels between the groups. In group 1, mean of diabetes duration was 9.2 years, and patients had various micro- and macro-vascular complications with various degrees and received various drugs for various diseases (Table 1).

**Postprandial levels**

In postprandial levels after TM, mean PG at each time point was significantly higher in group 1 than in group 2, whereas mean insulinogenic index was significantly (P<0.001) lower in group 1 (0.23 ± 0.08) than in group 2 (3.13 ± 0.17). However, there were no significant differences in mean of s-IRI, s-CPR or p-active GLP-1-S at each time point between two groups, although the peak levels of p-active GLP-1-S in both groups were observed at 30 min after TM (Figure 1).

In the term of AUC, mean PG was significantly (p<0.001) higher in group 1 (681 ± 26 mg/dL) than in group 2 (307 ± 11 mg/dL). However, there were no significant differences in s-IRI (50 ± 7 μU min/mL versus 51 ± 4 μU min/mL, respectively), s-CPR (9.3 ± 0.8 ng min/mL versus 9.2 ± 0.5 ng min/mL, respectively) and p-active GLP-1-S (16.1 ± 1.4 pmol min/L versus 18.7 ± 2.8 pmol min/L, respectively) levels between two groups.

**Discussion**

The patients were Japanese with T2DM, who had non-obesity with a tendency of insulin resistance based on the criteria of Matthews et al. [7] and low insulin secretion associated with low early-phase after TM which was confirmed by higher HOMA-R, lower HOAMA-β values and lower insulinogenic index than by those in control group, although there were insignificant differences in means of s-IRI and s-CPR in fasting and postprandial levels after TM between both groups. As patients had long durations of diabetes with mean of 9.2 years, some patients had micro- and macro-vascular complications with various severities varied, and had various medicines without incretin-related drugs.

There were no significant differences in fasting and postprandial p-active GLP-1-S levels after TM between groups similar to the report of Lee et al. [3], and the peaked time point of s-active GLP-1-S after TM was also same in two studies. However, the peaked level (around 5 pmol/L) in the study by Lee et al. [3] was slightly lower than that of our study. The difference may be due to the differences of total caloric contents used as TM (480 kcal versus 520-560 kcal). Recently, the Japan Diabetes Society and the Japan Association for Diabetes Education and Care Committee for Standardized Incretin Measurement recommends strongly that when p-active GLP-1 is measured, it should be measured the sample extracted by ethanol or other methods [8]. The reason is due to that foreign substances in unextracted samples might interfere in the assay [9]. However, p-active GLP-1 levels to response to ingestion of TM in unextracted samples measured by ELISA kit used in this study were correlated to p-total GLP-1 levels measured by RIA kit in extracted samples [10]. Also, Yi et al. showed p-active GLP-1 level measured by this kit in unextracted sample by mass spectrometry analyzing was almost active GLP-1 [11]. Moreover, means of p-active GLP-1 levels measured by ELISA kit used in this study in extracted samples of non-obese Japanese patients with T2DM (n=41) [9] were similar to those in the study with unextracted samples by Lee at al. [3], although the variation was higher in unextracted samples than in extracted samples [9].

Another difference between our findings and those of Lee et al. is the glycemic state. Mean HbA1c (9.1±0.3 %) (NGSP) in our patients was significantly (p<0.001) higher than that (6.8 ± 0.5 %) (NGSP) in patients by Lee et al. [3]. Hyperglycemia evaluated by HbA1c levels increases serum DPP-IV activity in patients with T2DM [11]. Moreover, serum DPP-IV activity is positively correlated to HbA1c levels in patients with T2DM [13]. Hence, the increased DPP-IV activity in the patients by this study should result in lower p-active GLP-1 levels. However, the findings in the patients were similar to those in the healthy individuals. Therefore, the glycemic state may not be directly related to these similar results.

The most difference between Lee et al. and our studies was the difference in demographic characteristics of patients participated.
The patients by Lee et al. were newly diagnosed as diabetes, had no complications and did not use medical drugs [3]. Therefore, patients by Lee et al. were complication- and treatment-naïve for T2DM, but our patients were not naïve. However, there was no statistical difference (r=0.002, p=0.820, n=22) in association between the AUCs of p-active GLP-1-S and the duration of diabetes. Yabe et al. [9] reported there was no significant difference in p-active GLP-1 levels with AUC following ingestion of TM between extracted samples of non-obese Japanese patients with T2DM and controls, whose durations of disease were similar to those in this study.

Further, SU or T2D did not influence the secretion of active GLP-1 [9,14,15], while α-GI or BG may enhance the secretion of active GLP-1 [16,17]. Hence, the p-active GLP-1 levels in patients treated with α-GI (n=1) or BG (n=15) in this study should result in higher than those in control. However, actual levels of p-active GLP-1-S were similar to those in the healthy individuals. The reason is not clarified, but some researchers reported therapy combined of α-GI or BG and DPP-IV inhibitors or GLP-1 agonist in patients with T2DM enhanced or increased plasma GLP-1-S levels significantly [16,17]. Also, anti-hyperlipidemic or anti-hypertensive medicines do not influence secretion of active GLP-1.

In some diabetic complications, autonomic neuropathy may decrease incretin effect [18], whereas chronic renal failure (serum creatinine 2.2 ± 0.9 mg/dl) may result in delayed elimination of GLP-1 secretin [19]. Although we did not precisely examine autonomic neuropathy as others laboratory tests as previously reported methods [2,20], the patients did not complain the clinical symptoms such as orthotic hypotension, awareness hypoglycemia or other related disturbances. Autonomic neuropathy is related to duration of disease. However, Yabe et al. [9] reported there was no significant difference in p-active GLP-1 levels with AUC following ingestion of TM between extracted samples of non-obese Japanese patients with T2DM and controls, whose durations of disease were similar to those in this study. Also, Toft-Nielsen et al. reported there was no statistical association between p-active GLP-1 levels and autonomic neuropathy in patients with T2DM [20]. Further, although one patient in this study had macroalbuminuria, the serum creatinine levels were less than 1.0 mg/dl with more than 60mL/minute/1.73 m2 of GFR. Therefore, these factors do not influence p-active GLP-1-S levels in this study as indication by Toft-Nielsen et al. [20].

It is well known that the post prandial levels of the other incretin GIP are similar between T2DM and healthy individuals [2,3]. However, we did not measure postmeal GIP levels. It would be interesting in future study to evaluate the incretin effect in the subjects by measuring insulin or C peptide after 75g OGTT and after isoglycemic IV glucose infusion.

Conclusion

Our results indicated that basal and postprandial levels of plasma active GLP-1-S after a test meal in non-obese Japanese patients with T2DM associated with a long duration of the disease, various complications and various treatments except related-incretin drugs were similar to those in non-obese healthy individuals.

Acknowledgments

We are grateful to clinical nursing staffs, clinical laboratory technicians and clinical dietitians of Nagaoka Red Cross Hospital and Niigata Medical Center for their valuable technical assistance.

References